Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

Incyte

Status and phase: Active, not recruiting; Phase 2

Conditions: B-Cell Malignancies

Treatments: Drug: parsaclisib + itacitinib; Drug: parsaclisib + ruxolitinib; Drug: parsaclisib + ibrutinib; Drug: Parsaclisib

Study type: Interventional

Funder types: Industry

Identifiers

NCT04509700

INCB 50465-801

Details and patient eligibility

About

This is a Phase 2, multicenter, open-label study to provide continued supply of parsaclisib as monotherapy or in combination therapy with itacitinib, ruxolitinib, or ibrutinib to participants from Incyte-sponsored studies of parsaclisib.

Full description

The purpose of this study is to provide continued use of parsaclisib as monotherapy or in combination with itacitinib, ruxolitinib, or ibrutinib to participants who are currently enrolled in an Incyte-sponsored study and receiving the same treatment, who have at least stable disease, who are obtaining clinical benefit (in the opinion of the investigator) on the current study treatment, as defined by the parent Protocol, and who are unable to access parsaclisib as monotherapy or in combination with itacitinib, ruxolitinib, or ibrutinib outside a clinical study. Participants will continue on the same dose and schedule as the ones being administered in the Incyte-sponsored parent Protocol at the time of the rollover. The study will collect and assess safety information with regards to AEs.

Enrollment: 112 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Currently enrolled and receiving treatment in an Incyte-sponsored clinical study of parsaclisib.
• Currently tolerating treatment in the parent Protocol.
• Currently receiving clinical benefit from treatment with parsaclisib as monotherapy or in combination therapy with Itacitinib, ruxolitinib, or ibrutinib as determined by the investigator.
• Has at least stable disease, as determined by the investigator.
• Has demonstrated compliance, as assessed by the investigator, with the parent Protocol requirements.
• Willingness and ability to comply with scheduled visits, treatment plans, including PJP prophylaxis, and any other study procedures indicated in this Protocol.
• Willingness to avoid pregnancy or fathering children
• Ability to comprehend and willingness to sign an ICF

Exclusion criteria

• Has been permanently discontinued from study treatment in the parent Protocol for any reason.
• Able to access parsaclisib as monotherapy or in combination with itacitinib, ruxolitinib, or ibrutinib therapy outside a clinical study.
• Participants with an uncontrolled intercurrent illness or any concurrent condition that, in the investigator's opinion, would jeopardize the safety of the participant or compliance with the Protocol.
• Pregnant or breastfeeding women.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

112 participants in 4 patient groups

parsaclisib

Experimental group

Description:

Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib as that provided in the parent Protocol at the time of the rollover.

Treatment:

Drug: Parsaclisib

parsaclicib + itacitinib

Experimental group

Description:

Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and 100 mg of itacitinib as that provided in the parent Protocol at the time of the rollover.

Treatment:

Drug: parsaclisib + itacitinib

parsaclisib + ruxolitinib

Experimental group

Description:

Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and the same dose of ruxolitinib that was provided in the parent Protocol at the time of the rollover.

Treatment:

Drug: parsaclisib + ruxolitinib

parsaclisib + ibrutinib

Experimental group

Description:

Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and 140 mg of ibrutinib as that provided in the parent Protocol at the time of the rollover.

Treatment:

Drug: parsaclisib + ibrutinib